[go: up one dir, main page]

AR045094A1 - Formulaciones liofilizadas de cci-779 - Google Patents

Formulaciones liofilizadas de cci-779

Info

Publication number
AR045094A1
AR045094A1 ARP040102625A ARP040102625A AR045094A1 AR 045094 A1 AR045094 A1 AR 045094A1 AR P040102625 A ARP040102625 A AR P040102625A AR P040102625 A ARP040102625 A AR P040102625A AR 045094 A1 AR045094 A1 AR 045094A1
Authority
AR
Argentina
Prior art keywords
cci
preparing
lyophilized
lcifilized
formulations
Prior art date
Application number
ARP040102625A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34115376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR045094(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR045094A1 publication Critical patent/AR045094A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Método para preparar una formulación de CCI-779 liofilizado. Formulación de CCI-779 liofilizado. Método para preparar CCI-779 para administrar en forma líquida. Formas de dosificación líquida de CCI-779. Método para potenciar la estabilidad durante el almacenamiento de CCI-779 y kit. Reivindicación 1: Una solución útil para preparar CCI-779 liofilizado, dicha solución comprende 0,1 mg/ml a 250mg/ml de CCI-779 y por lo menos 30% v/v de solvente seleccionado del grupo formado por dimetilsulfóxido, acetonitrilo, etanol, isopropanol, t-butil alcohol, y sus mezclas que contienen, en forma opcional, agua.
ARP040102625A 2003-07-25 2004-07-23 Formulaciones liofilizadas de cci-779 AR045094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49029303P 2003-07-25 2003-07-25

Publications (1)

Publication Number Publication Date
AR045094A1 true AR045094A1 (es) 2005-10-12

Family

ID=34115376

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102625A AR045094A1 (es) 2003-07-25 2004-07-23 Formulaciones liofilizadas de cci-779

Country Status (20)

Country Link
US (1) US20050020615A1 (es)
EP (1) EP1648454A1 (es)
JP (1) JP2007500191A (es)
KR (1) KR20060052880A (es)
CN (1) CN1829514A (es)
AR (1) AR045094A1 (es)
AU (1) AU2004261163A1 (es)
BR (1) BRPI0412916A (es)
CA (1) CA2532251A1 (es)
CO (1) CO5680425A2 (es)
CR (1) CR8153A (es)
EC (1) ECSP066394A (es)
IL (1) IL172573A0 (es)
MX (1) MXPA05013865A (es)
NO (1) NO20056178L (es)
RU (1) RU2345772C2 (es)
SG (1) SG144165A1 (es)
TW (1) TW200505501A (es)
WO (1) WO2005011688A1 (es)
ZA (1) ZA200600684B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040693A1 (es) 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
ES2298861T3 (es) * 2004-01-08 2008-05-16 Wyeth Composicion farmaceutica que puede obtenerse mediante compresion directa para la administracion oral de cci-779.
US7393952B2 (en) 2004-08-27 2008-07-01 Cordis Corporation Solvent free amorphous rapamycin
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
US7582312B2 (en) * 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
JP5670335B2 (ja) * 2008-09-25 2015-02-18 セファロン、インク． ベンダムスチン液体製剤
CA2749101A1 (en) * 2009-01-15 2010-07-22 Cephalon, Inc. Novel forms of bendamustine free base
WO2011151704A2 (en) * 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
EP2811984B1 (en) 2012-02-06 2015-08-26 Fresenius Kabi Oncology Limited Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
CN102940630A (zh) * 2012-11-16 2013-02-27 浙江海正药业股份有限公司 含有西罗莫司酯化物的药物组合物及其制备方法
WO2014118696A2 (en) * 2013-01-29 2014-08-07 Gland Pharma Limited Pharmacuetical compositions of rapamycin esters and its derivatives
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN104510708B (zh) * 2013-09-29 2018-04-24 正大天晴药业集团股份有限公司 一种米铂冻干制剂及其制备方法
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
CN105687132B (zh) * 2016-03-17 2020-06-12 鲁南贝特制药有限公司 一种坦西莫司注射用浓溶液及其制备方法
CN107773539A (zh) * 2016-08-27 2018-03-09 鲁南制药集团股份有限公司 一种注射用坦西莫司及其制备方法
CN111165656A (zh) * 2020-01-09 2020-05-19 南京大学（溧水）生态环境研究院 一种黑水虻冻干粉高效制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204775B (it) * 1986-01-31 1989-03-10 Rosella Silvestrini Kit per la determinazione dell'attivita' proliferativa nei tumori umani
US5352783A (en) * 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
DK0833828T3 (da) * 1995-06-09 2003-03-17 Novartis Ag Rapamycinderivater
GB9514594D0 (en) * 1995-07-17 1995-09-13 Johnson & Johnson Clin Diag Chemiluminescent analytical method
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
DE19936281C2 (de) * 1999-08-02 2002-04-04 Bayer Ag Verfahren zur Gefriertrocknung
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
CA2416976C (en) * 2000-08-11 2008-05-20 Wyeth Treatment of estrogen receptor positive carcinoma with a rapamycin and an antiestrogen
US6399625B1 (en) * 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
AR040693A1 (es) * 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
JP2006506353A (ja) * 2002-09-17 2006-02-23 ワイス 経口処方
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція

Also Published As

Publication number Publication date
CR8153A (es) 2006-05-26
WO2005011688A1 (en) 2005-02-10
MXPA05013865A (es) 2006-02-28
KR20060052880A (ko) 2006-05-19
CO5680425A2 (es) 2006-09-29
JP2007500191A (ja) 2007-01-11
TW200505501A (en) 2005-02-16
SG144165A1 (en) 2008-07-29
IL172573A0 (en) 2006-04-10
NO20056178L (no) 2006-02-17
EP1648454A1 (en) 2006-04-26
CA2532251A1 (en) 2005-02-10
RU2345772C2 (ru) 2009-02-10
CN1829514A (zh) 2006-09-06
ECSP066394A (es) 2006-08-30
ZA200600684B (en) 2008-07-30
RU2006105645A (ru) 2006-06-27
US20050020615A1 (en) 2005-01-27
BRPI0412916A (pt) 2006-09-26
AU2004261163A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
AR045094A1 (es) Formulaciones liofilizadas de cci-779
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
AR048017A1 (es) Composicion y metodo para aumentar la biodisponibilidad
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
AR017979A1 (es) Formulaciones farmaceuticas de epotilonas, metodo para su preparacion y el uso de los mismos para la manufactura de un medicamento
PE20050066A1 (es) Formulaciones farmaceuticas liquidas de palonosetron
ECSP003847A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
CL2010000816A1 (es) Formulacion adecuada para administracion subcutanea que comprende al menos 100 mg/ml de ctlaig, un azucar, y un portador acuoso farmaceuticamente estable; articulo de fabricacion que comprende al menos un recipiente que contiene la formulacion antes mencionada. (divisional solicitud n° 3597-06)
AR033221A1 (es) Composicion farmaceutica finamente autoemulsionable
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
CR7583A (es) Nueva sal formiato de o-desmetil venlafaxina
PT1267832E (pt) Sistema auto-emulsionante de libertacao de farmaco
CO6190598A2 (es) Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales
AR011846A1 (es) Una composicion farmaceutica, y el procedimiento para prepararla
AR044050A1 (es) Utilizacion de ivermectina para el tratamiento de desordenes dermatologicos
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
AR027360A1 (es) Composicion farmaceutica
SE0000774D0 (sv) New formulation
AR032642A1 (es) Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponibilidad oral.
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
CO5560585A2 (es) Formulacion farmaceutica para administracion intramuscular de fulvestrant
DK1212039T3 (da) Sammensætning til inhalation omfattende delta-9-tetrahydrocannabinol i et semivandigt oplösningsmiddel
ES2195538T3 (es) Composicion farmaceutica que comprende una combinacion de isomeros dextro y levo de sotalol.

Legal Events

Date Code Title Description
FB Suspension of granting procedure